A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases

Author： Howell A.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.82, Iss.3, 2003-01, pp. : 215-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

Letrozole: An Updated Review of its Use in Postmenopausal Women with Advanced Breast Cancer

By Keating G.M.   Jarvis B.  

American Journal of Cancer, Vol. 1, Iss. 5, 2002-01 ,pp. : 351-371

Adis International

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

By Skedgel C.   Rayson D.   Dewar R.   Younis T.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 325-333

Springer Publishing Company

Access to resources Recommend Favorite